Page 480 - Petelin, Ana, in Helena Skočir. 2020. Ur. Raziskovanje za znanje, znanje za zdravje. Zbornik prispevkov z recenzijo. Koper: Založba Univerze na Primorskem.
P. 480
iskovanje za znanje, znanje za zdravje PINTAR, TOPOLOVEC, V., 2019. Kakovost življenja bolnikovz Mielodisplastičnim sindromom
pri zdravljenju s transfuzijo: diplomsko delo. Maribor: Alma Mater Europaea-Evropski
center Maribor, str. 1-36.
PORTER, J., in VIPRAKASIT, V., 2014. Iron overload and chelation. In: CAPPELLINI, M. D.,
COHEN, A., PORTER, J., TAHER, A., VIPRAKASIT, V., editors. Guidelines for the manage-
ment of transfusion dependent thalassaemia (TDT) [Internet]. 3rd edition. Nicosia (CY):
Thalassaemia international federation; Chapter 3. Pridobljeno 10.10.2019 s https://
www.ncbi.nlm.nih.gov/books/NBK269373/
ROSE, C., BRECHIGNAC, S., VASSILIEF, D., PASCAL, L., STAMATOULLAS, A., GUERCI, A., LAR�-
BAA, D., DREYFUS, F., BEYNE-RAUZY, O., CHAURYH, PIERRE, M., ROY, L., CHEZE, S., MO-
REL, P., in FENAUX, P., 2010. Does iron chelation therapy improve survival in regularly
transfused lower risk MDS patients? A multicenter study by the GFM. Leukemia Rese-
arch, 34 (7): 864 – 870.
SEVER, M., PODGORNIK, H., MLAKAR, U., in ČERNELČ, P., 2012. Lastnosti bolnikov z mielo�-
displastičnim sindromom in njihova obravnava na kliničnem oddelku za hematolo-
gijo, UKC Ljubljana, v obdobju 2008-2012. Zdravstveni Vestnik, 81 (supl 29): II - 41- 48.
SOUSA, K., in KWOK O., 2006. Putting Wilson and Cleary to the Test: Analysis of a HRQOL
conceptual model using structural equation modeling. Quality of Life Research, 15 (4):
725 – 737.
STEENSMA, P. D., HEPTINSTALL, V. K., JOHNSON, M. V., NOVOTNY P. J., SLOAN, J. A., CAMO-
RIANO, J. K., NIBLACK, J., BENNETT J. M., in MESA R. A., 2008. Common troublesome
symptoms and their impact on quality of life in patients with myelodysplastic syn-
dromes (MDS): Results of a large internet-based survey. Leukemia Research, 32 (5): 691
– 698.
UHAN, M., 2018. Mielodisplastični sindrom - MDS - Vodnik za bolnike. Mengeš. Društvo bol-
nikov s krvnimi boleznimi Slovenije: 9 - 21.
478
pri zdravljenju s transfuzijo: diplomsko delo. Maribor: Alma Mater Europaea-Evropski
center Maribor, str. 1-36.
PORTER, J., in VIPRAKASIT, V., 2014. Iron overload and chelation. In: CAPPELLINI, M. D.,
COHEN, A., PORTER, J., TAHER, A., VIPRAKASIT, V., editors. Guidelines for the manage-
ment of transfusion dependent thalassaemia (TDT) [Internet]. 3rd edition. Nicosia (CY):
Thalassaemia international federation; Chapter 3. Pridobljeno 10.10.2019 s https://
www.ncbi.nlm.nih.gov/books/NBK269373/
ROSE, C., BRECHIGNAC, S., VASSILIEF, D., PASCAL, L., STAMATOULLAS, A., GUERCI, A., LAR�-
BAA, D., DREYFUS, F., BEYNE-RAUZY, O., CHAURYH, PIERRE, M., ROY, L., CHEZE, S., MO-
REL, P., in FENAUX, P., 2010. Does iron chelation therapy improve survival in regularly
transfused lower risk MDS patients? A multicenter study by the GFM. Leukemia Rese-
arch, 34 (7): 864 – 870.
SEVER, M., PODGORNIK, H., MLAKAR, U., in ČERNELČ, P., 2012. Lastnosti bolnikov z mielo�-
displastičnim sindromom in njihova obravnava na kliničnem oddelku za hematolo-
gijo, UKC Ljubljana, v obdobju 2008-2012. Zdravstveni Vestnik, 81 (supl 29): II - 41- 48.
SOUSA, K., in KWOK O., 2006. Putting Wilson and Cleary to the Test: Analysis of a HRQOL
conceptual model using structural equation modeling. Quality of Life Research, 15 (4):
725 – 737.
STEENSMA, P. D., HEPTINSTALL, V. K., JOHNSON, M. V., NOVOTNY P. J., SLOAN, J. A., CAMO-
RIANO, J. K., NIBLACK, J., BENNETT J. M., in MESA R. A., 2008. Common troublesome
symptoms and their impact on quality of life in patients with myelodysplastic syn-
dromes (MDS): Results of a large internet-based survey. Leukemia Research, 32 (5): 691
– 698.
UHAN, M., 2018. Mielodisplastični sindrom - MDS - Vodnik za bolnike. Mengeš. Društvo bol-
nikov s krvnimi boleznimi Slovenije: 9 - 21.
478
